Is ABVX or IDYA more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% IDEAYA Biosciences N/A -14.24% -13.09%

Does the media refer more to ABVX or IDYA?

In the previous week, Abivax had 23 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 29 mentions for Abivax and 6 mentions for IDEAYA Biosciences. Abivax's average media sentiment score of 0.04 beat IDEAYA Biosciences' score of 0.00 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 4 Very Positive mention(s) 6 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is IDYA or PRAX more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Praxis Precision Medicines N/A -43.02% -40.22%

Does the media favor IDYA or PRAX?

In the previous week, Praxis Precision Medicines had 20 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 6 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.00 beat Praxis Precision Medicines' score of -0.08 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Praxis Precision Medicines 3 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IDYA or CYTK?

In the previous week, Cytokinetics had 4 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 10 mentions for Cytokinetics and 6 mentions for IDEAYA Biosciences. Cytokinetics' average media sentiment score of 0.12 beat IDEAYA Biosciences' score of 0.00 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cytokinetics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IDYA or KRYS?

In the previous week, Krystal Biotech had 2 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for Krystal Biotech and 6 mentions for IDEAYA Biosciences. Krystal Biotech's average media sentiment score of 0.58 beat IDEAYA Biosciences' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IDYA or IBRX?

In the previous week, ImmunityBio had 2 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for ImmunityBio and 6 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.00 beat ImmunityBio's score of -0.19 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

IDEAYA Biosciences (IDYA) Competitors

$28.29 -0.93 (-3.18%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$27.28 -1.02 (-3.59%)

As of 06/5/2026 06:40 PM Eastern

Compare

IDYA vs. ABVX, PRAX, CYTK, KRYS, and IBRX

Should you buy IDEAYA Biosciences stock or one of its competitors? MarketBeat compares IDEAYA Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IDEAYA Biosciences include Abivax (ABVX), Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Krystal Biotech (KRYS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does IDEAYA Biosciences compare to Abivax?

Abivax (NASDAQ:ABVX) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

IDEAYA Biosciences' return on equity of -14.24% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

IDEAYA Biosciences has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
IDEAYA Biosciences	$218.71M	11.36	-$113.70M	-$1.60	N/A

Abivax has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

Abivax currently has a consensus target price of $130.08, suggesting a potential upside of 28.12%. IDEAYA Biosciences has a consensus target price of $50.69, suggesting a potential upside of 79.17%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Abivax had 23 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 29 mentions for Abivax and 6 mentions for IDEAYA Biosciences. Abivax's average media sentiment score of 0.04 beat IDEAYA Biosciences' score of 0.00 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	4 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

47.9% of Abivax shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

IDEAYA Biosciences beats Abivax on 11 of the 14 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Praxis Precision Medicines?

IDEAYA Biosciences (NASDAQ:IDYA) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

IDEAYA Biosciences has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market.

In the previous week, Praxis Precision Medicines had 20 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 6 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.00 beat Praxis Precision Medicines' score of -0.08 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Praxis Precision Medicines	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	11.36	-$113.70M	-$1.60	N/A
Praxis Precision Medicines	$8.55M	828.25	-$303.27M	-$13.37	N/A

IDEAYA Biosciences currently has a consensus price target of $50.69, indicating a potential upside of 79.17%. Praxis Precision Medicines has a consensus price target of $572.72, indicating a potential upside of 125.48%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

IDEAYA Biosciences' return on equity of -14.24% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

IDEAYA Biosciences beats Praxis Precision Medicines on 10 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Cytokinetics?

IDEAYA Biosciences (NASDAQ:IDYA) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

IDEAYA Biosciences has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Cytokinetics	-784.02%	N/A	-52.86%

98.3% of IDEAYA Biosciences shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Cytokinetics had 4 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 10 mentions for Cytokinetics and 6 mentions for IDEAYA Biosciences. Cytokinetics' average media sentiment score of 0.12 beat IDEAYA Biosciences' score of 0.00 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cytokinetics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

IDEAYA Biosciences has higher revenue and earnings than Cytokinetics. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	11.36	-$113.70M	-$1.60	N/A
Cytokinetics	$88.04M	101.03	-$784.96M	-$6.84	N/A

IDEAYA Biosciences presently has a consensus price target of $50.69, indicating a potential upside of 79.17%. Cytokinetics has a consensus price target of $99.30, indicating a potential upside of 38.92%. Given IDEAYA Biosciences' higher possible upside, equities analysts clearly believe IDEAYA Biosciences is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Cytokinetics beats IDEAYA Biosciences on 9 of the 17 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Krystal Biotech?

IDEAYA Biosciences (NASDAQ:IDYA) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Krystal Biotech has a net margin of 53.92% compared to IDEAYA Biosciences' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Krystal Biotech	53.92%	19.25%	17.62%

IDEAYA Biosciences presently has a consensus target price of $50.69, suggesting a potential upside of 79.17%. Krystal Biotech has a consensus target price of $324.11, suggesting a potential upside of 7.68%. Given IDEAYA Biosciences' higher possible upside, equities analysts clearly believe IDEAYA Biosciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Krystal Biotech had 2 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for Krystal Biotech and 6 mentions for IDEAYA Biosciences. Krystal Biotech's average media sentiment score of 0.58 beat IDEAYA Biosciences' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Krystal Biotech has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	11.36	-$113.70M	-$1.60	N/A
Krystal Biotech	$389.13M	22.80	$204.83M	$7.48	40.24

Summary

Krystal Biotech beats IDEAYA Biosciences on 13 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to ImmunityBio?

IDEAYA Biosciences (NASDAQ:IDYA) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

IDEAYA Biosciences currently has a consensus target price of $50.69, indicating a potential upside of 79.17%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 105.20%. Given ImmunityBio's higher possible upside, analysts clearly believe ImmunityBio is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

IDEAYA Biosciences has higher revenue and earnings than ImmunityBio. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	11.36	-$113.70M	-$1.60	N/A
ImmunityBio	$113.29M	63.97	-$351.40M	-$0.85	N/A

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 69.5% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, ImmunityBio had 2 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for ImmunityBio and 6 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.00 beat ImmunityBio's score of -0.19 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

IDEAYA Biosciences has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
ImmunityBio	-606.15%	N/A	-59.53%

IDEAYA Biosciences has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

Summary

IDEAYA Biosciences and ImmunityBio tied by winning 8 of the 16 factors compared between the two stocks.

Get IDEAYA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDYA vs. The Competition

Export

Metric	IDEAYA Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.49B	$3.34B	$6.66B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.56%
P/E Ratio	-17.68	18.69	24.03	23.62
Price / Sales	11.36	300.26	514.26	110.64
Price / Cash	N/A	51.45	26.99	37.22
Price / Book	2.42	7.97	10.24	6.66
Net Income	-$113.70M	$23.89M	$3.57B	$337.55M
7 Day Performance	-4.00%	-6.96%	-1.28%	-2.52%
1 Month Performance	0.18%	-2.80%	1.38%	-0.03%
1 Year Performance	30.19%	36.80%	23.93%	25.34%

IDEAYA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDYA IDEAYA Biosciences	2.7197 of 5 stars	$28.29 -3.2%	$50.69 +79.2%	+30.2%	$2.49B	$218.71M	N/A	80	Analyst Forecast
ABVX Abivax	3.4782 of 5 stars	$129.73 +2.6%	$137.15 +5.7%	+1,139.7%	$10.07B	N/A	N/A	61	News Coverage Analyst Forecast Options Volume
PRAX Praxis Precision Medicines	2.8606 of 5 stars	$357.13 +1.9%	$592.67 +66.0%	+470.0%	$9.77B	$8.55M	N/A	110	News Coverage Analyst Forecast Analyst Revision
CYTK Cytokinetics	2.8552 of 5 stars	$77.15 +1.1%	$99.30 +28.7%	+121.3%	$9.49B	$88.04M	N/A	250
KRYS Krystal Biotech	3.0415 of 5 stars	$306.63 +1.3%	$324.11 +5.7%	+119.8%	$8.92B	$389.13M	40.99	210	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDYA) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. ABVX, PRAX, CYTK, KRYS, and IBRX

How does IDEAYA Biosciences compare to Abivax?

Summary

How does IDEAYA Biosciences compare to Praxis Precision Medicines?

Summary

How does IDEAYA Biosciences compare to Cytokinetics?

Summary

How does IDEAYA Biosciences compare to Krystal Biotech?

Summary

How does IDEAYA Biosciences compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. ABVX, PRAX, CYTK, KRYS, and IBRX

How does IDEAYA Biosciences compare to Abivax?

Is ABVX or IDYA more profitable?

Which has higher earnings and valuation, ABVX or IDYA?

Which has more risk & volatility, ABVX or IDYA?

Do analysts prefer ABVX or IDYA?

Does the media refer more to ABVX or IDYA?

Do institutionals & insiders hold more shares of ABVX or IDYA?

Summary

How does IDEAYA Biosciences compare to Praxis Precision Medicines?

Which has more risk and volatility, IDYA or PRAX?

Does the media favor IDYA or PRAX?

Which has better valuation and earnings, IDYA or PRAX?

Do analysts prefer IDYA or PRAX?

Is IDYA or PRAX more profitable?

Do insiders & institutionals have more ownership in IDYA or PRAX?

Summary

How does IDEAYA Biosciences compare to Cytokinetics?

Is IDYA or CYTK more profitable?

Do institutionals & insiders believe in IDYA or CYTK?

Does the media refer more to IDYA or CYTK?

Which has more risk & volatility, IDYA or CYTK?

Which has preferable earnings and valuation, IDYA or CYTK?

Do analysts prefer IDYA or CYTK?

Summary

How does IDEAYA Biosciences compare to Krystal Biotech?

Is IDYA or KRYS more profitable?

Do analysts recommend IDYA or KRYS?

Does the media favor IDYA or KRYS?

Which has more volatility and risk, IDYA or KRYS?

Do institutionals and insiders hold more shares of IDYA or KRYS?

Which has preferable valuation & earnings, IDYA or KRYS?

Summary

How does IDEAYA Biosciences compare to ImmunityBio?

Do analysts rate IDYA or IBRX?

Which has preferable earnings and valuation, IDYA or IBRX?

Do insiders and institutionals believe in IDYA or IBRX?

Does the media prefer IDYA or IBRX?

Is IDYA or IBRX more profitable?

Which has more volatility & risk, IDYA or IBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools